- Cannabis has been classified as a Schedule I controlled substance under the federal Controlled Substances Act (CSA) since 1970 — the most restrictive federal drug classification.
- Schedule I requires that DEA determine a substance has high abuse potential, no currently accepted medical use, and a lack of accepted safety data — all three criteria are contested by existing research.
- IRS Section 280E prohibits cannabis businesses from deducting standard business expenses, producing effective tax rates of 40–70% — compared to the standard 21% corporate rate.
- FDIC-insured banks cannot knowingly accept cannabis business proceeds without regulatory risk, forcing most cannabis operators into cash-heavy operations despite state-level legality.
- The DOJ's informal non-enforcement policy is not law and has been reversed before — state-legal operators remain technically subject to federal prosecution under the Supremacy Clause.
- The DEA proposed rescheduling cannabis to Schedule III in 2024; this would not legalize cannabis but would remove the 280E burden and ease research barriers.
- Federal employees, security clearance holders, and residents of federal housing remain subject to zero-tolerance cannabis policies regardless of state law.
Cannabis as a Schedule I Substance: The CSA Classification
The legal foundation of federal cannabis prohibition is the Controlled Substances Act, signed into law by President Nixon in 1970. The CSA created a five-schedule classification system for controlled substances, with Schedule I reserved for drugs deemed to have the highest abuse potential and no accepted medical use. Cannabis was placed in Schedule I alongside heroin — a placement initially described as provisional, pending review by the Shafer Commission. The Shafer Commission recommended decriminalization in 1972. Nixon ignored the recommendation entirely. Cannabis has remained Schedule I ever since.
For a substance to qualify as Schedule I under the DEA's criteria, three conditions must be met: (1) the drug has a high potential for abuse; (2) it has no currently accepted medical use in treatment in the United States; and (3) there is a lack of accepted safety for use under medical supervision. All three criteria are now actively challenged by existing scientific evidence, the FDA approval of Epidiolex (a cannabis-derived CBD medication), and the DEA-licensed medical research that has occurred since 1970. The contradiction between Schedule I's formal requirements and the current state of cannabis medicine is the central legal tension driving rescheduling proceedings.
What Schedule I Means in Practice
Schedule I classification carries specific practical consequences that extend far beyond criminal penalties:
- DEA enforcement authority: The DEA can investigate, arrest, and prosecute cannabis cultivation, distribution, and possession as federal crimes regardless of state law. Penalties include significant prison terms and asset forfeiture.
- Research barriers: Schedule I researchers require DEA registration, NIDA-supplied research cannabis (historically of limited quality), FDA oversight, and institutional review board approval. These layered requirements have significantly slowed clinical research compared to Schedule II substances like cocaine and methamphetamine.
- FDA jurisdiction: Because cannabis is Schedule I, the FDA cannot regulate it as a food, dietary supplement, or pharmaceutical without a separate approval process — which is why cannabis products sold at dispensaries do not carry FDA approval (with the single exception of Epidiolex).
- Banking: Federal financial institutions regulated by the FDIC or Federal Reserve cannot knowingly accept proceeds from cannabis sales without risk of federal regulatory action, effectively excluding cannabis businesses from standard commercial banking.
- Taxation: IRS Section 280E, discussed below, applies specifically to Schedule I and II substances — meaning rescheduling to Schedule III would eliminate it.
Federal vs. State Law: The Supremacy Clause and DOJ Policy
The coexistence of state-legal cannabis markets with federal prohibition is legally awkward. Under the Supremacy Clause of the US Constitution, federal law is the supreme law of the land, and when federal and state law directly conflict, federal law prevails. This means that every cannabis dispensary in California, Colorado, or any other legal state is technically operating in violation of federal law, regardless of their state license.
The practical resolution of this conflict has been prosecutorial discretion — DOJ decisions not to prioritize enforcement against state-legal actors — rather than legal resolution. The key memos governing this policy have a turbulent history:
- Ogden Memo (2009): Deputy AG Ogden directed US Attorneys not to prioritize prosecution of individuals who use or cultivate cannabis for medical purposes in compliance with state law.
- Cole Memo (2013): Deputy AG James Cole expanded this guidance to cover recreational markets, establishing eight enforcement priorities (preventing youth access, preventing interstate trafficking, etc.) and implicitly tolerating state-legal operations that addressed those priorities.
- Sessions Memo (2018): Attorney General Jeff Sessions rescinded the Cole Memo without explanation, restoring prosecutorial discretion to individual US Attorneys. This created significant uncertainty but did not trigger a wave of enforcement against state-legal operators.
- Garland Policy (2021-present): Attorney General Merrick Garland reinstated informal non-interference with state-legal cannabis markets during confirmation hearings and through DAG guidance, functionally restoring Cole Memo-era approach without formally reissuing it.
The critical takeaway: this non-enforcement policy is not law, is not codified in statute, and can be reversed by any incoming administration without congressional action. State-legal cannabis businesses operate under a presidentially revocable tolerance, not a legal safe harbor.
Who Can Be Prosecuted: Realistic Federal Enforcement Priorities
Despite the theoretical federal risk faced by all state-legal cannabis operators, actual federal prosecution under current policy concentrates on specific categories: interstate trafficking (transporting cannabis across state lines even between two legal states); operations on federal land (national parks, forests, military bases); large-scale money laundering connected to cannabis proceeds; and operations explicitly violating state law under the guise of a state license. Individual consumers in legal states face minimal federal risk under current policy.
Section 280E: The Tax Code That Defines Cannabis Business
No single provision of federal law has more day-to-day operational impact on legal cannabis businesses than IRS Section 280E. Enacted in 1982 in response to a drug dealer's successful argument that he could deduct business expenses for his cocaine operation, 280E prohibits any business that "traffics in controlled substances" (defined by Schedule I or II) from deducting ordinary and necessary business expenses from their federal taxable income.
For a standard business, deductible expenses include rent, wages, utilities, insurance, marketing, professional services, and interest on debt — the full range of costs required to operate. Under 280E, cannabis businesses can deduct only the cost of goods sold (COGS) — direct costs attributable to production of the product itself (wholesale acquisition cost, direct cultivation labor, packaging materials). Everything else is nondeductible.
The financial impact is severe. A cannabis dispensary that earns $5 million in annual revenue and has $4 million in total expenses — typical industry margins — might owe federal taxes on $3.5 million of income (revenue minus COGS of $1.5M) rather than $1 million (revenue minus all expenses). This translates to effective federal tax rates of 40–70%, compared to the 21% standard corporate rate. Many profitable cannabis businesses report negative after-tax cash flow specifically because of 280E.
"280E is not a tax on cannabis — it is a confiscation of income from a legal business imposed by a classification decision made in 1970 that has not been legislatively revisited since."
Rescheduling cannabis to Schedule III would eliminate 280E's application immediately, since 280E applies only to Schedule I and II substances. This single change would substantially improve the financial viability of the legal cannabis industry without requiring any other legislative action on cannabis specifically.
Banking: Why Legal Cannabis Is Largely Unbanked
The banking problem in cannabis is structural, not attitudinal. FDIC-insured banks and credit unions that knowingly accept deposits from cannabis businesses risk being found to be facilitating federal money laundering and drug trafficking offenses under the Bank Secrecy Act. Regulators can require suspicious activity reports (SARs), freeze accounts, or revoke charters. Even banks sympathetic to cannabis businesses face regulatory examination risk simply by maintaining cannabis accounts.
The result is that a substantial portion of US cannabis retail operates primarily in cash — receiving cash payments from customers, paying vendors in cash, paying employees in cash, and transporting large amounts of physical currency to pay state taxes. This creates security vulnerabilities (cannabis businesses are disproportionately targeted for robbery), tax compliance complexity, and an inability to use basic financial tools like credit card processing, business lines of credit, or payroll processing services.
Some credit unions and smaller state-chartered banks have established cannabis banking programs, filing preemptive SARs on all cannabis-related transactions and operating under state regulatory guidance. But these institutions represent a small fraction of the financial system, and their cannabis services typically carry premium fees and restrictions not imposed on other industries.
The SAFE Banking Act (Secure and Fair Enforcement Banking Act) would create a federal safe harbor for financial institutions serving state-legal cannabis businesses, prohibiting federal banking regulators from penalizing banks solely for providing services to licensed cannabis operators. It has passed the House of Representatives seven times. As of 2025, it has not passed the Senate. Its advocates argue it is the single most impactful near-term legislative fix for the cannabis industry, independent of rescheduling or legalization.
Cannabis and Federal Employment, Clearances & Housing
Federal law's reach extends beyond the criminal justice system into employment and housing in ways that directly affect consumers in legal states.
Federal employees: All federal government employees are subject to federal drug-free workplace requirements regardless of state law. Federal agencies can — and do — discipline and terminate employees for off-duty cannabis use even in fully legal states. This applies to direct federal employees, contractors with federal agencies, and recipients of certain federal grants and contracts.
Security clearances: The federal security clearance process evaluates cannabis use as a drug use issue under federal law. Recent or regular cannabis use is a standard basis for clearance denial or revocation, even if the use occurred legally in a legal state. Some agencies have updated guidance to be more contextual about prior use, but active cannabis use by clearance holders remains a significant compliance risk.
Federal housing: Residents of public housing administered by the US Department of Housing and Urban Development (HUD) are subject to lease clauses prohibiting illegal drug use as defined by federal law. Cannabis use — even if legal under state law — can constitute grounds for lease termination in federally subsidized housing. Local housing authorities vary in how aggressively they enforce this, but the federal policy framework has not changed.
Veterans and the VA: VA physicians are prohibited from recommending cannabis to patients because it is federally illegal. However, VA policy since 2017 prohibits denying veterans other VA services — including opioid pain management — solely because they use cannabis. Veterans can discuss cannabis use with VA providers without it affecting their care access, but cannot receive a VA cannabis recommendation or prescription.
Interstate Commerce: The State-Line Problem
Even between two states that have fully legalized adult-use cannabis, transporting cannabis across the state border is a federal felony under the Controlled Substances Act's interstate trafficking provisions. Federal jurisdiction over interstate commerce is explicit and broad under the Commerce Clause, and cannabis transported across state lines — regardless of the legal status at origin and destination — falls under federal law.
This prohibition has significant practical implications. Cannabis produced in Oregon cannot be legally shipped to Washington or California, even though all three states have legal recreational markets. This eliminates the cost efficiencies that come from agricultural specialization and regional production at scale — the same efficiencies that make California wine, Idaho potatoes, or Florida citrus economically viable as national products. Each state must maintain its own cultivation and production sector regardless of comparative advantage.
Some cannabis advocates and legal scholars argue that interstate cannabis commerce could eventually be structured under a federal licensing framework, similar to interstate alcohol commerce under the Federal Alcohol Administration Act. But this would require either federal legalization or specific interstate commerce legislation that has not yet been introduced in actionable form.
Schedule III Rescheduling: What Would Actually Change
The DEA's 2024 proposal to reschedule cannabis from Schedule I to Schedule III is the most significant federal cannabis action since 1970, and understanding exactly what it would and would not change is essential for consumers and businesses alike.
| Issue | Schedule I (Current) | Schedule III (Proposed) |
|---|---|---|
| Federal legality | Federally prohibited | Still federally controlled; not legalized |
| 280E tax deductions | No business expense deductions allowed | Full business expense deductions restored |
| Banking access | FDIC banks cannot serve cannabis businesses | Unclear — additional rulemaking likely required |
| Clinical research | DEA Schedule I researcher registration required; complex approval | Significantly streamlined; standard Schedule III research pathways |
| FDA oversight | Cannot regulate cannabis as food/supplement/drug without separate process | FDA drug approval pathways become more accessible |
| Interstate commerce | Interstate trafficking prohibited | Still prohibited — CSA interstate provisions unchanged |
| Federal employment | Zero tolerance under federal drug-free workplace policy | Policy unchanged — Schedule III substances still subject to drug testing |
| State law preemption | Federal law technically preempts state law | Federal law still technically preempts state law |
Full federal legalization would require congressional action — either the Cannabis Administration and Opportunity Act (CAOA) or the MORE Act (Marijuana Opportunity Reinvestment and Expungement Act). Both have been introduced but neither has passed both chambers of Congress. The CAOA would federally legalize cannabis, establish a federal regulatory framework modeled on tobacco and alcohol, provide for expungement of prior federal cannabis convictions, and create federal revenue from cannabis taxation. Its passage remains a medium-term policy objective for reform advocates.